anastrozole and Indigestion studies

anastrozole and Indigestion

anastrozole has been researched along with Indigestion in 1 studies

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."	9.14	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."	5.14	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Markopoulos, C	1
Tzoracoleftherakis, E	1
Polychronis, A	1
Venizelos, B	1
Dafni, U	1
Xepapadakis, G	1
Papadiamantis, J	1
Zobolas, V	1
Misitzis, J	1
Kalogerakos, K	1
Sarantopoulou, A	1
Siasos, N	1
Koukouras, D	1
Antonopoulou, Z	1
Lazarou, S	1
Gogas, H	1

Studies

Markopoulos, C

Tzoracoleftherakis, E

Polychronis, A

Venizelos, B

Dafni, U

Xepapadakis, G

Papadiamantis, J

Zobolas, V

Misitzis, J

Kalogerakos, K

Sarantopoulou, A

Siasos, N

Koukouras, D

Antonopoulou, Z

Lazarou, S

Gogas, H

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484]		220 participants (Actual)	Observational	2004-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484]

220 participants (Actual)

Observational

2004-05-31

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for anastrozole and Indigestion

Article	Year
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast cancer research : BCR, 2010, Volume: 12, Issue:2 Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit	2010

Article

Year

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Breast cancer research : BCR, 2010, Volume: 12, Issue:2

Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit

2010